http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2694837-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d7ec54e77f01fbfd3703ae971ad32e8c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2022 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-22 |
| filingDate | 2017-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d4d938d96a24e801b269c9aadd28ef8d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5dbaac46851dd357a82fb617e68b8b6f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe2b2b773a4aa202ebd9883d56c3c256 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ec4f17312b38087b91593d0655dcf376 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_36b91b70505fd682d13388155c3596c0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_930dfe5b5f8c15661208a5df080f43ad http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1d9686b0e1302761add113f8cc900ff0 |
| publicationDate | 2019-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2694837-C2 |
| titleOfInvention | Prolonged action pharmaceutical composition based on 5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole dihydrochloride and/or base (aphobazolum) |
| abstract | FIELD: medicine.SUBSTANCE: invention relates to medicine, in particular to a pharmaceutical composition having anxiolytic action and containing as a medicinal agent a therapeutically effective amount of Aphobazolum - 5-ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole dihydrochloride and/or base, and as additional pharmaceutically acceptable components, which impart novel consumer properties to the drug on the basis of the declared composition: a combination of release modifiers, specifically, a release retarder and a hydrophilic release modifier, with a certain quantitative ratio thereof, as well as a group of substances providing a sufficient mass of the dosage form, binding substances, sliding/lubricating substances, and film casing. Aphobazolum-based dosage forms can be presented both in the form of tablets, capsules, granules, powder, providing duration of action of the drug for at least 8 hours.EFFECT: implementation of the invention enables to obtain a pharmaceutical composition exhibiting prolonged release of the active pharmaceutical ingredient, which enables to stabilize the concentration of the preparation in the human body for a day and thereby reduce the frequency of taking the preparation for a day to achieve the desired therapeutic effect.6 cl, 14 tbl, 2 dwg |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110092945-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110092945-B |
| priorityDate | 2017-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 86.